2LB Stock Chart & Stats
€3.20
-€0.05(-0.70%)
At close: 4:00 PM EST
€3.20
-€0.05(-0.70%)
Day’s Range― - ―
52-Week Range€1.57 - €4.74
Previous CloseN/A
Volume0.00
Average Volume (3M)525.00
Market Cap
€1.96B
Enterprise Value€1.20K
Total Cash (Recent Filing)€313.44M
Total Debt (Recent Filing)€47.78M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume160
30 Day Avg. Volume525
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.61Price Target Upside168.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)€317.25M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Growth And AdoptionSustained commercial traction with meaningful TTM revenue and strong quarterly growth indicates durable product-market fit for lifileucel. Rising physician awareness and growing ATC network expand the addressable patient flow, supporting repeatable per-patient sales and a steadily growing revenue base over the next 2–6 months.
In-house Manufacturing Control And Capacity RestorationRestoring and owning manufacturing capacity reduces supply risk and improves unit economics long-term. In-house modular capacity enables higher throughput, better COGS control and faster geographic expansion, which are structural advantages for scaling an autologous cell-therapy business.
Low Leverage And Multi-year RunwayA modest debt burden and several quarters of cash runway provide durable operational flexibility to execute commercialization and registrational trials without immediate refinancing. This structural liquidity buffer supports milestone delivery and measured investment pacing over the medium term.
Bears Say
High Cash Burn And Negative Cash FlowLarge, persistent negative operating and free cash flows mean the business consumes significant liquidity as it scales. Over a 2–6 month horizon this structural cash burn necessitates continued financing or expense cuts and raises execution risk if revenue growth or funding access slows.
Deep Net Losses And Capital ErosionDespite revenue gains, sizable ongoing net losses and negative ROE indicate the company is still eroding shareholder capital. Until operating profitability or sustained positive cash generation is achieved, capital consumption remains a structural headwind to long-term shareholder value.
Dependence On Regulatory, Enrollment Milestones And ATM UsageCommercial expansion and projected peak sales hinge on successful regulatory approvals and trial enrollment. Coupled with ongoing ATM equity taps, this structural reliance on external capital and milestone delivery raises dilution and execution risk across the medium term if regulatory or enrollment setbacks occur.
Iovance Biotherapeutics News
2LB FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was €1.57 and its highest was €4.74 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is €1.96B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -€0.167 earnings per share for the quarter, missing the consensus estimate of -€0.135 by -€0.032.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.11.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -€0.167 in its last earnings report, missing expectations of -€0.135. Following the earnings report the stock price went up 1.471%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in DE:2LB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.61 (168.98% Upside)
€8.61 (168.98% Upside)
Blogger Sentiment
Bullish
DE:2LB Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
2LB Stock 12 Month Forecast
Average Price Target
€8.61
▲(168.98% Upside)